Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Hyloris Lines Up Hectic Year Of Clinical Trials And Major US Launch
Hyloris has an eventful year ahead as it plans to conduct numerous trials for products in its ever-expanding pipeline and launch Maxigesic IV in the US.
Fresh Competition Coming For Narcan In US
Further US hybrid and generic rivals to Narcan are in the works, with Amphastar having just received an FDA nod for its naloxone nasal spray in a proprietary device as Amneal files an ANDA for a further generic version.
Coherus Pulls A Rabbit Out Of The Hat With Inventive Pegfilgrastim Form
Coherus’ year-end financial results included a surprise – a newly approved formulation of pegfilgrastim.
Rovi’s Value-Added US Risperidone Gets New Goal Date, Teva Ruled Out As Partner
Spain’s Laboratorios Farmacéuticos Rovi has a firm date to remedy issues observed in its application for a hybrid version of risperidone, developed using Rovi’s proprietary ISM drug-release technology platform.
What’s Next? Five Things To Look Out For In March
Prepare for all the biggest industry actions and events in March 2023 with Generics Bulletin’s monthly column.
GGB Awards Returns To Barcelona In Its 10th Year
Celebrating its tenth anniversary year, the Global Generics & Biosimilars Awards 2023 will take place on Wednesday 25 October in Barcelona, Spain.
Hyloris Partner Signs To Market Maxigesic IV In Central And Eastern Europe
Hyloris’ partner AFT has signed an exclusive licensing and distribution agreement with Salus Pharmaceuticals covering nine central and eastern European countries. Meanwhile, Hyloris has also struck an in-licensing deal for a new blood phosphorus deficiency treatment.
What’s Next? Five Things To Look Out For In February
February brings a potentially sizeable launch in the US, multiple court cases in both the US and Europe and a gala generics and biosimilars event stretching across four days in Florida.
Teva-MedinCell Alliance Heats Up With Second Phase III Trial Underway
Teva’s partnership with MedinCell for long-acting injectable products, first penned a decade ago, is beginning to gather steam, as another candidate entered the clinic ahead of a potential first approval in the coming months.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.